

RACE Trial

A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anaemia patients

A study by the Severe Aplastic Anaemia Working Party (SAAWP)
Principal Investigators: Antonio Risitano and Régis Peffault de Latour.

Grant providers: Novartis and Pfizer



Trial Objective

The primary objective of this trial is to investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated aplastic anaemia patients.

The Race trial is a prospective open label randomised phase III trial aiming to change standard practice in SAA.

	Treatment	Dose (units)	Treatment Period
Arm A (standard):	ATGAM	40 mg/kg/day, iv	Day 1, 2, 3 and 4
	Cyclosporine A	5 mg/kg/day, po	Day 1-365
Arm B: arm A + Investigational drug	Eltrombopag	150 mg every 24 h, po	Day 14-90 (or 14-180)

Primary endpoint: Rate of Complete Response at 3 months since start of treatment in naive severe AA patients.

CR is defined as: Hb>10 g/dL, ANC>1,000/μL and Platelets>100,000 μL


Country Status (data per 21 February 2018)

Country	N° of open sites	N° of enrolling sites	N° of randomised subjects
France	7	7	58
Italy	5	3	14
Netherlands	4	4	19
Spain	3	2	4
Switzerland	1	1	6
United Kingdom	4	3	23
Total	24	20	124

Main Inclusion Criteria

- Diagnosis of severe or very severe aplastic anemia, defined by:
 - At least two of the following:
 - Absolute neutrophil counts <0,5 x 10⁹/L (severe) or <0,2 x 10⁹/L (very severe)
 - Platelets counts <20 x 10⁹/L
 - Reticulocyte counts <60 x 10⁹/L
 - Hypocellular bone marrow (<30% cellularity without evidences of fibrosis or malignant cells)
- Male or female age ≥ 15 years


Treatment schema



Legenda:
EPAG = Eltrombopag
hATG = ATGAM
CsA = Cyclosporin

Note 1: time is not depicted linearly. With ⚡ we indicate a variable time span between 2 weeks and 6 months after stop EPAG treatment.
Note 2: patients with NR at 6 months FU are considered treatment failures and should receive rescue treatment chosen by PI. Only patients in arm A are eligible for 3 up to 6 month EPAG as salvage treatment within the RACE trial.

Accrual



The CTO team

Clinical Trials Operating Manager

Marianne Mol ebmcto@lumc.nl

Clinical Trials Coordinators

Alain Barrois, Dilyana Georgieva, Annelies Kleijne, Marleen van Os, Janette Symons and

Sofie Terwel (RACE Trial Project Coordinator) racetrial@lumc.nl



EBMT Clinical Trials Office Leiden

Rijnsburgerweg 10
2333 AA Leiden
The Netherlands

Tel: +31 (0)71 526 5005
Fax: +31 (0)71 526 6185

